Octagon Capital Advisors LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Octagon Capital Advisors LP disclosed 26 US equity positions worth $1.1bn in its Q2 2026 13F filing. The largest position was DNTH at 16.5% of the reported book, followed by DFTX and ABVX. Against the Q1 2026 filing, it opened 4 new positions, added to 4 and reduced 6 among the top 26 holdings.
What did Octagon Capital Advisors LP own in Q2 2026? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 16.5% | $179.5m | 1,841,667 | -5% | reduced |
| 2 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 12.7% | $138.8m | 2,950,000 | 21% | added |
| 3 | ABVX ABIVAX SA | Healthcare | 12.1% | $132.3m | 993,000 | 47% | added |
| 4 | COGT COGENT BIOSCIENCES INC | Healthcare | 8.3% | $90.9m | 2,350,000 | 0% | held |
| 5 | ALMS ALUMIS INC | Healthcare | 7.3% | $79.7m | 2,830,700 | 0% | held |
| 6 | AVBP ARRIVENT BIOPHARMA INC | Healthcare | 6.3% | $68.5m | 1,971,054 | 0% | held |
| 7 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 6.1% | $66.0m | 9,693,244 | 9% | added |
| 8 | BIOA BIOAGE LABS INC | 3.9% | $42.8m | 1,748,000 | 0% | held | |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 3.6% | $39.7m | 338,900 | 0% | held |
| 10 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 3.3% | $35.5m | 310,000 | -27% | reduced |
| 11 | AKTS AKTIS ONCOLOGY INC | 2.8% | $31.0m | 960,847 | 0% | held | |
| 12 | XENE XENON PHARMACEUTICALS INC | Healthcare | 2.7% | $29.6m | 490,000 | 0% | held |
| 13 | PALI PALISADE BIO INC | Healthcare | 2.0% | $21.5m | 10,276,317 | 0% | held |
| 14 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.9% | $20.4m | 2,075,000 | -34% | reduced |
| 15 | IRON DISC MEDICINE INC | Healthcare | 1.8% | $19.7m | 270,000 | 0% | held |
| 16 | SMMT SUMMIT THERAPEUTICS INC | Healthcare | 1.7% | $18.2m | 1,250,000 | – | new |
| 17 | PHVS PHARVARIS N V | Healthcare | 1.4% | $15.8m | 456,721 | 177% | added |
| 18 | ANL ADLAI NORTYE LTD | 1.0% | $10.7m | 934,716 | – | new | |
| 19 | DTIL PRECISION BIOSCIENCES INC | 1.0% | $10.6m | 1,350,000 | -40% | reduced | |
| 20 | DBVT DBV TECHNOLOGIES S A | 0.9% | $9.4m | 574,200 | 0% | held | |
| 21 | FTH FAETH THERAPEUTICS INC | 0.8% | $9.0m | 361,010 | – | new | |
| 22 | GYRE GYRE THERAPEUTICS INC | 0.6% | $6.3m | 954,416 | – | new | |
| 23 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.5% | $5.9m | 315,000 | -79% | reduced |
| 24 | UNCY UNICYCIVE THERAPEUTICS INC | 0.4% | $4.7m | 1,000,000 | 0% | held | |
| 25 | CNTX CONTEXT THERAPEUTICS INC | 0.2% | $1.7m | 3,050,000 | -42% | reduced | |
| 26 | GOSS GOSSAMER BIO INC | Healthcare | 0.1% | $1.3m | 7,750,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.